4,415 results found

In Intuitive Surgical, Inc. v. Ethicon LLC, No. 2020-1481 (Fed. Cir. Feb. 11, 2022), the Federal Circuit affirmed that Intuitive was estopped under § 315(e)(1)...

In Ford Motor Co. v. Paice LLC, IPR2015-00787, Paper 35 (Oct. 21, 2016), the Board dismissed Ford's inter partes review (IPR) challenge of a claim based on estoppel under 35 U.S.C. § 315(e)(1)...

In this special edition Finnegan podcast, Erika Arner and Kevin Rodkey discuss the PTAB's precedential decision in Apple Inc. vs. Fintiv Inc. and the effects it has had on PTAB practice, ...

Welcome to the Last Month at the Federal Circuit—a look at recent Federal Circuit decisions impacting the intellectual property community.

In this special two-episode podcast series, Finnegan partner Jeffrey Totten chats with Finnegan attorney Alissa Green about the Federal Circuit's inaugural ruling...

Welcome to the Last Month at the Federal Circuit – a look at recent Federal Circuit decisions impacting the intellectual property community.

Welcome to the Last Month at the Federal Circuit – a look at recent Federal Circuit decisions impacting the intellectual property community.

In June 2017, the Supreme Court announced its decisions in Sandoz v. Amgen and Amgen v. Sandoz – cases that examined how makers of biosimilars and branded biologic drugs bring products to market.

Welcome to the Last Month at the Federal Circuit—a look at recent Federal Circuit decisions impacting the intellectual property community.

Welcome to the Last Month at the Federal Circuit—a look at recent Federal Circuit decisions impacting the intellectual property community.

On April 24, 2018, the Supreme Court handed down two opinions in cases related to inter partes review (IPR). In a 7-2 decision, the Court upheld the constitutionality of IPRs in Oil States Energy Services...

In Merck Sharp & Dohme Corp. v. Hospira, Inc., No. 2017-1115 (Fed. Cir. Oct. 26, 2017), a divided Federal Circuit panel affirmed the district court's finding that a claimed process for making a chemical compound was obvious.

In AlexSam, Inc. v. Aetna, Inc., No. 22-2036 (Fed. Cir. Oct. 8, 2024), the Federal Circuit found the district court erred in its evaluation of a license agreement...

On December 5, 2019, the Counterfeit Goods Seizure Act of 2019 (CGSA) was introduced to the U.S. Senate. If enacted into law, the CGSA would allow U.S. Customs and Border Protection...

With 2019 in the rear-view mirror and 2020 in full swing, we take a moment to reflect on what posts rose to the top during 2019. Here is a listing of the Prosecution First's top five posts in 2019:

In Bio-Rad Labs., Inc. v. 10X Genomics Inc., No. 2019-2255 (Fed. Cir. Aug. 3, 2020), the Federal Circuit rejected 10X's prosecution history

At the USPTO, Patent Center is the next-generation system that incorporates all application submission types and file management functionality currently available in EFS-Web and Private PAIR...

The USPTO's e-Petitions cannot be granted for petitions to revive an abandoned application if: